ABBV · Forward model · Other key products
What has to happen in Other key products
Model as of
This page changes Other key products inside the complete ABBV model. Every other vertical, corporate programme and valuation assumption stays in the selected portfolio case.
Shares this vertical and portfolio case. Slider and horizon edits stay in your browser.
Other key products
Basis quarter$935M
Final quarter$842M
Implied CAGR−2%
Final revenue mix4%
Mavyret, Creon and Linzess: three mature, mostly US products disclosed by revenue only. $935M in 2026 Q2, -9.8% year over year, with Mavyret down 22.2% operationally as the treated hepatitis C population shrinks.
Last four quarters
2025 Q3
$1.01B
Reported
2025 Q4
$884M
Reported
2026 Q1
$995M
Reported
2026 Q2
$935M
Reported
MavyretCreonLinzess
Sequential growth
−0.8%/qtr
decaying toward −0.3%
-0.8% a quarter. The eight-quarter sequential rate is -0.35% and the last year -2.6%; this sits between them.
Other key products
Latest: $842M (2031Q2E)
| Period | Value |
|---|---|
| 2023Q3 | $963M |
| 2023Q4 | $968M |
| 2024Q1 | $900M |
| 2024Q2 | $962M |
| 2024Q3 | $874M |
| 2024Q4 | $912M |
| 2025Q1 | $809M |
| 2025Q2 | $1.04B |
| 2025Q3 | $1.01B |
| 2025Q4 | $884M |
| 2026Q1 | $995M |
| 2026Q2 | $935M |
| 2026Q3E | $928M |
| 2026Q4E | $921M |
| 2027Q1E | $914M |
| 2027Q2E | $908M |
| 2027Q3E | $902M |
| 2027Q4E | $897M |
| 2028Q1E | $892M |
| 2028Q2E | $887M |
| 2028Q3E | $882M |
| 2028Q4E | $878M |
| 2029Q1E | $874M |
| 2029Q2E | $870M |
| 2029Q3E | $866M |
| 2029Q4E | $862M |
| 2030Q1E | $859M |
| 2030Q2E | $855M |
| 2030Q3E | $852M |
| 2030Q4E | $849M |
| 2031Q1E | $846M |
| 2031Q2E | $842M |
Assumptions & reasoning
- Aseasonal by evidence: the window-to-window spread of 6.0 to 10.2pp exceeds the apparent seasonal signal on every single quarter, so encoding factors here would encode noise.
- The line is genuinely lumpy quarter to quarter - deseasonalised sequential moves in the disclosed history run from -19.9% to +18.3% - so the level, not any one quarter's growth rate, is the input. Linzess grew 41.8% for the half on a US basis that includes a comparability change.
- Model FY2026 is $3.78B against $3.74B reported for FY2025, falling to $3.42B by FY2030.